Skip to Content
Due to a recent surge in pediatric RSV and flu, we are allowing only visitors 18 years of age and older in our general inpatient (hospital) settings at this time for the safety of our patients, in line with Illinois Department of Public Health guidance. Read More

Liver Disease/Hepatology Clinical Trials

A Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP-HE)
Aims: The purpose of this study is to evaluate the safety and efficacy of OCR-002 administered via continuous intravenous (IV) infusion to hospitalized patients with cirrhosis, hyperammonemia, and an acute episode of hepatic encephalopathy Stages 2-4. The primary endpoint is time to confirmed clinical response defined as a reduction to Stage 2 or  improvement to Stage 0/1. 
Diagnosis: Hepatic Encephalopathy
Principal Investigator
: Dhiren Shah, MD
Other Investigator:
Jonathan Williams, DO
IRB Approval Number: EH 14-183
Sponsor: Ocera Therapeutics
Contact:  Interested patients should contact study coordinator Boris Jancan, CCRP at 847.570.1583
Open to Enrollment: